Clinical Trial: tACS Modulates Speech and Cognitive Impairments in People With PD by Targeting the Medial Frontal Cortex

U.S., Nov. 21 -- ClinicalTrials.gov registry received information related to the study (NCT07240272) titled 'tACS Modulates Speech and Cognitive Impairments in People With PD by Targeting the Medial Frontal Cortex' on Sept. 26.

Brief Summary: This clinical trial aims to study whether transcranial alternating current stimulation (tACS) applied to the medial frontal cortex (MFC) can improve speech and cognitive function in people with Parkinson's disease (PD), and to evaluate the safety of tACS. The main goals are to answer the following questions:

1. Can tACS stimulation of the MFC improve executive functions in people with PD (such as reasoning, planning, inhibition, and complex problem-solving)?

2. Can it improve the integration of audi...